Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 324.80% | 274.31% | -59.09% | -53.36% | -74.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 324.80% | 274.31% | -59.09% | -53.36% | -74.12% |
| Cost of Revenue | 5.02% | -15.47% | -12.98% | -4.05% | 39.95% |
| Gross Profit | -4.30% | 15.99% | 12.73% | 3.78% | -41.36% |
| SG&A Expenses | 140.65% | 120.95% | 80.29% | 48.67% | 35.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.42% | 34.84% | 20.80% | 15.46% | 38.10% |
| Operating Income | -62.08% | -34.57% | -21.08% | -15.70% | -38.89% |
| Income Before Tax | -62.64% | -35.05% | -22.29% | -16.16% | -43.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.64% | -35.05% | -22.29% | -16.16% | -43.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.64% | -35.05% | -22.29% | -16.16% | -43.49% |
| EBIT | -62.08% | -34.57% | -21.08% | -15.70% | -38.89% |
| EBITDA | -62.29% | -34.69% | -21.09% | -15.59% | -41.80% |
| EPS Basic | -20.53% | -4.80% | -2.53% | -2.51% | -32.14% |
| Normalized Basic EPS | -20.47% | -4.78% | -2.53% | -2.53% | -29.87% |
| EPS Diluted | -20.53% | -4.80% | -2.53% | -2.51% | -32.14% |
| Normalized Diluted EPS | -20.47% | -4.78% | -2.53% | -2.53% | -29.87% |
| Average Basic Shares Outstanding | 32.91% | 27.62% | 19.37% | 13.71% | 11.97% |
| Average Diluted Shares Outstanding | 32.91% | 27.62% | 19.37% | 13.71% | 11.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |